Literature DB >> 24534079

Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon β.

Catherine Larochelle1, François Grand'maison2, Gilles P Bernier3, Mathieu Latour4, Jean-François Cailhier5, Alexandre Prat6.   

Abstract

Three women aged 34-47 years old, on high dose interferon beta-1a for relapsing-remitting multiple sclerosis, were hospitalized between 2009-2012 for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Patients sought medical attention for neurological symptoms including cephalalgia, blurred vision, confusion, focal deficits and seizures. All patients presented thrombocytopenia, hemolytic anemia and arterial hypertension. Despite plasma exchanges, corticosteroids and anti-CD20 treatments, all patients progressed towards severe renal insufficiency and one patient died of hemorrhagic shock. In this report we identify a rare but morbid complication of interferon beta-1a treatment associated with female gender, Caucasian background and low body mass index.
© The Author(s) 2014.

Entities:  

Keywords:  Multiple sclerosis; hemolytic anemia; interferon beta; renal insufficiency; thrombocytopenia; thrombotic thrombocytopenic purpura-hemolytic uremic syndrome

Mesh:

Substances:

Year:  2014        PMID: 24534079     DOI: 10.1177/1352458514523692

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  14 in total

1.  Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report.

Authors:  Haruomi Nishio; Tatsuo Tsukamoto; Takeshi Matsubara; Yoichiro Okada; Ryosuke Takahashi; Motoko Yanagita
Journal:  CEN Case Rep       Date:  2016-06-20

Review 2.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

Review 3.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606

4.  Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients.

Authors:  Tatiana Koudriavtseva; Domenico Plantone; Rosaria Renna; Chiara Mandoj; Diana Giannarelli; Caterina Mainero
Journal:  Neurol Sci       Date:  2015-07-26       Impact factor: 3.307

Review 5.  Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.

Authors:  Maria Pia Amato; Emilio Portaccio
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 6.  Type I interferon dysregulation and neurological disease.

Authors:  Sarah McGlasson; Alexa Jury; Andrew Jackson; David Hunt
Journal:  Nat Rev Neurol       Date:  2015-08-25       Impact factor: 42.937

7.  Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature.

Authors:  David Kavanagh; Sarah McGlasson; Alexa Jury; Jac Williams; Neil Scolding; Chris Bellamy; Claudia Gunther; Diane Ritchie; Daniel P Gale; Yashpal S Kanwar; Rachel Challis; Holly Buist; James Overell; Belinda Weller; Oliver Flossmann; Mark Blunden; Eric P Meyer; Thomas Krucker; Stephen J W Evans; Iain L Campbell; Andrew P Jackson; Siddharthan Chandran; David P J Hunt
Journal:  Blood       Date:  2016-09-23       Impact factor: 25.476

8.  Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a.

Authors:  Ali-Frédéric Ben-Amor; Anton Trochanov; Tanya Z Fischer
Journal:  Adv Ther       Date:  2015-05-20       Impact factor: 3.845

9.  Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.

Authors:  Guttorm Raknes; Lars Småbrekke
Journal:  PLoS One       Date:  2017-11-03       Impact factor: 3.240

10.  Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab.

Authors:  Marco Allinovi; Calogero Lino Cirami; Leonardo Caroti; Giulia Antognoli; Silvia Farsetti; Maria Pia Amato; Enrico Eugenio Minetti
Journal:  Clin Kidney J       Date:  2017-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.